H.C. Wainwright reiterates Rani Therapeutics stock rating on FDA program acceptance

H.C. Wainwright has reaffirmed its Buy rating for Rani Therapeutics (NASDAQ: RANI) and set a $11.00 price target, following the company's announcement of its RaniPill platform being accepted into the FDA's Emerging Technology Program (ETP). The investor relations firm highlighted that this acceptance provides a formal mechanism for identifying and understanding the regulatory requirements for the RaniPill, paving the way for a more clearly defined set of FDA requirements.

The acceptance also enables Rani Therapeutics to identify the work necessary to unlock the platform's value and create a pathway for an Investigational New Drug application in the U.S. The company's stock, currently trading at $0.77, appears undervalued based on the InvestingPro analysis. H.C. Wainwright noted that the company maintains a strong balance sheet with more cash than debt and a current ratio of 5.31, although it is rapidly using up cash, which is typical for biotech firms in the development stage.

The acceptance of RaniPill into the FDA's ETP is seen as a significant step for Rani Therapeutics, as it facilitates the transition from regulatory dialogue to a more defined set of FDA requirements. This development is expected to expedite the process of opening an Investigational New Drug application in the U.S. and potentially establish a broader regulatory framework that can be applied to future RaniPill programs.

Additionally, Rani Therapeutics reported better-than-expected earnings per share of $(0.04) against FactSet's estimate of $(0.05) and research and development expenses of $5.0 million, which were lower than the anticipated $5.5 million. The company also held $53.4 million in cash and marketable securities at the end of the quarter.

Rani Therapeutics has also made a strategic partnership with PegBio to explore the oral delivery of molecules for obesity and metabolic disease, further expanding its R&D efforts.